Analysts expect Sienna Senior Living Inc. (TSE:SIA) to report $0.28 EPS on May, 8.They anticipate $0.07 EPS change or 20.00% from last quarter’s $0.35 EPS. T_SIA’s profit would be $17.81M giving it 16.06 P/E if the $0.28 EPS is correct. After having $0.33 EPS previously, Sienna Senior Living Inc.’s analysts see -15.15% EPS growth. The stock increased 0.45% or $0.08 during the last trading session, reaching $17.99. About 86,353 shares traded. Sienna Senior Living Inc. (TSE:SIA) has 0.00% since April 16, 2017 and is . It has underperformed by 11.55% the S&P500.
Akcea Therapeutics Inc (NASDAQ:AKCA) had an increase of 34.6% in short interest. AKCA’s SI was 5.14M shares in April as released by FINRA. Its up 34.6% from 3.82M shares previously. With 294,300 avg volume, 18 days are for Akcea Therapeutics Inc (NASDAQ:AKCA)’s short sellers to cover AKCA’s short positions. The SI to Akcea Therapeutics Inc’s float is 34.67%. The stock decreased 3.62% or $0.84 during the last trading session, reaching $22.34. About 45,355 shares traded. Akcea Therapeutics, Inc. (NASDAQ:AKCA) has 0.00% since April 16, 2017 and is . It has underperformed by 11.55% the S&P500.
Sienna Senior Living Inc., through its subsidiaries, provides senior housing and long-term care services in Canada. The company has market cap of $1.14 billion. It operates through LTC business, Retirement, and Baltic divisions. It has a 39.98 P/E ratio. The firm owns and operates 35 LTC homes across Ontario with 5,733 beds; and 13 retirement residences representing 1,429 suites in the provinces of Ontario and British Columbia.
Among 5 analysts covering Sienna Senior Living Inc. (TSE:SIA), 0 have Buy rating, 0 Sell and 5 Hold. Therefore 0 are positive. Sienna Senior Living Inc. had 25 analyst reports since August 12, 2015 according to SRatingsIntel. Scotia Capital maintained it with “Sector Perform” rating and $15.75 target in Wednesday, August 12 report. Scotia Capital maintained the shares of SIA in report on Friday, February 17 with “Sector Perform” rating. The company was maintained on Friday, August 12 by Scotia Capital. The stock of Sienna Senior Living Inc. (TSE:SIA) earned “Outperform” rating by RBC Capital Markets on Thursday, November 10. As per Tuesday, May 30, the company rating was maintained by BMO Capital Markets. The rating was maintained by Raymond James on Wednesday, April 19 with “Market Perform”.
Akcea Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The company has market cap of $1.49 billion. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. It currently has negative earnings. The firm also develops AKCEA-APO-LRx, which has completed Phase 2b clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase 1/2 clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase 1/2 study for the treatment of cardiovascular disease driven by high triglycerides.